Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vito Sasseville"'
Autor:
Jeffrey D. Kearns, Paul Wassmann, Ufuk Olgac, Marie Fichter, Brigitte Christen, Tina Rubic-Schneider, Stephan Koepke, Benjamin Cochin de Billy, David Ledieu, Cedric Andre, Stuart Hawtin, Benoit Fischer, Francesca Moretti, Christian Hug, Alexander Bepperling, Barbara Brannetti, Celia Mendez-Garcia, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. Grosskreutz, Pawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees, Anette C. Karle
Publikováno v:
Science Translational Medicine. 15
Immunogenicity against intravitreally administered brolucizumab has been previously described and associated with cases of severe intraocular inflammation, including retinal vasculitis/retinal vascular occlusion (RV/RO). The presence of antidrug anti
Autor:
Anette C. Karle, Matthias B. Wrobel, Stephan Koepke, Michael Gutknecht, Sascha Gottlieb, Brigitte Christen, Tina Rubic-Schneider, Ingrid Pruimboom-Brees, Xavier Charles Leber, Meike Scharenberg, Benjamin Maciejewski, Oliver Turner, Chandra Saravanan, Francois Huet, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. Grosskreutz, Jeffrey D. Kearns, Pawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees
Publikováno v:
Science Translational Medicine. 15
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. In 2020, rare cases of retinal vasculitis an
Autor:
Robert J. Adams, David M. Anderson, Stuart Baker, Matthew L. Banks, Wallace B. Baze, Cathy S. Carlson, Svetlana Chefer, Kari L. Christe, J. Mark Cline, Ricki Colman, Tony Comuzzie, Cheryl D. DiCarlo, Cynthia J. Doane, Richard Eberle, David B. Elmore, Jeffrey Everitt, Michele A. Fahey, Elizabeth W. Ford, James G. Fox, G. Gale Galland, Melaney K. Gee, Alfonso S. Gozalo, Lisa C. Halliday, Dana L. Hasselschwert, Michael J. Huerkamp, Matthew J. Kessler, Jans Langermans, David E. Lee-Parritz, Joseph L. Mankowski, Robert P. Marini, Amanda Martinot, Mark J. McArthur, Andrew Miller, Brandy Morenko, S. Stevens Negus, Thomas E. Nolan, Vito Sasseville, James R. Swearengen, Anita M. Trichel, Deborah E. Weiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4d0bf6aa24c1c45b26306614a8e3229
https://doi.org/10.1016/b978-0-12-381366-4.09001-5
https://doi.org/10.1016/b978-0-12-381366-4.09001-5
Publikováno v:
Molecular and Cellular Probes. 7:133-138
Mycoplasma pneumoniae-specific monoclonal antibodies were constructed for the purpose of developing reagents for clinical diagnostics. The monoclonal antibodies, designated Mp2B12 and Mp3A11, recognize surface exposed antigens of 28 kDa and 170 kDa,